EVALUATION OF 5 COMMERCIAL ANTIFUNGAL SUSCEPTIBILITY TESTING SYSTEMS

被引:16
|
作者
DRUETTA, A [1 ]
FREYDIERE, A [1 ]
GUINET, R [1 ]
GILLE, Y [1 ]
机构
[1] INST PASTEUR,CTR IMMUNOCHIM MICROBIENNE,F-69210 LARBRESLE,FRANCE
关键词
D O I
10.1007/BF01964429
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Five commercial antifungal susceptibility testing systems were studied for repeatability and reproducibility as well as concordance of results with the MICs for ten reference strains belonging to six different species. Repeatability was determined by testing each strain in triplicate on the same day, and reproducibility by repeating this triple determination on three different days. On the basis of 630 yeast-antifungal agent results for Mycototal and Mycostandard, 540 for Candifast, and 450 for ATB Fungus and Diff Test, repeatability was consistently equal to or greater than 95 %. Reproducibility was 80.07 % for Candifast and greater than 95 % for the other systems. The concordance with the reference MICs was 51.65 % for Candifast, 75.33 % for ATB Fungus, 80.89 % for Diff Test, 90.16 % for Mycostandard and 90.32 % for Mycototal. Although the performance of Diff Test and ATB Fungus was satisfactory, Mycototal and Mycostandard gave notably better results with imidazoles. Mycostandard, which is easier to use and includes tests for fluconazole and itraconazole, would seem to be potentially the most useful antifungal susceptibility test available at present.
引用
收藏
页码:336 / 342
页数:7
相关论文
共 50 条
  • [1] Evaluation of three commercial methods for antifungal susceptibility testing of 'non-grubii' Cryptococcus neoformans strains
    Colom Valiente, M. F.
    Linares, C.
    Hagen, F.
    Rosa, V.
    Torreblanca, M.
    MYCOSES, 2014, 57 : 45 - 45
  • [2] Trends in antifungal susceptibility testing using CLSI reference and commercial methods
    Canton, Emilia
    Espinel-Ingroff, Ana
    Peman, Javier
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) : 107 - 119
  • [3] Commercial methods for antifungal susceptibility testing of Candida: are they validated for patient care?
    Arendrup, M. C.
    Pfaller, M. A.
    MYCOSES, 2013, 56 : 16 - 16
  • [4] Evaluation of a new method for antifungal susceptibility testing for azoles
    Sabra, W.
    Tawfik, A. F.
    Shibl, A. M.
    WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY, 2010, 26 (03): : 451 - 457
  • [5] Evaluation of a new method for antifungal susceptibility testing for azoles
    W. Sabra
    A. F. Tawfik
    A. M. Shibl
    World Journal of Microbiology and Biotechnology, 2010, 26 : 451 - 457
  • [6] Interlaboratory evaluation of the Etest® for antifungal susceptibility testing of dermatophytes
    Fernández-Torres, B
    Carrillo-Muñoz, A
    Ortoneda, M
    Pujol, I
    Pastor, FJ
    Guarro, J
    MEDICAL MYCOLOGY, 2003, 41 (02) : 125 - 130
  • [7] Antifungal susceptibility testing
    Tudela, J. L. Rodriguez
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S65 - S65
  • [8] Antifungal susceptibility testing
    Fothergill, Annette W.
    Rinaldi, Michael G.
    Sutton, Deanna A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2006, 20 (03) : 699 - +
  • [9] ANTIFUNGAL SUSCEPTIBILITY TESTING
    REX, JH
    PFALLER, MA
    RINALDI, MG
    POLAK, A
    GALGIANI, JN
    CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (04) : 367 - 381
  • [10] Commercial Methods for Antifungal Susceptibility Testing of Yeasts: Strengths and Limitations as Predictors of Resistance
    Espinel-Ingroff, Ana
    JOURNAL OF FUNGI, 2022, 8 (03)